E-Posters-Improvement in Nocturia and Nightime Voiding over Twelve Weeks With a Percutaneous Tibial Neuromodulation System in Drug Naive Patients With Overactive Bladder Syndrome (OAB)

Improvement in Nocturia and Nightime Voiding over Twelve Weeks With a Percutaneous Tibial Neuromodulation System in Drug Naive Patients With Overactive Bladder Syndrome (OAB) - Victor W. Nitti, MD

Back to course

Pdf Summary

The study evaluated the efficacy of percutaneous tibial neuromodulation (PTNM) in reducing nocturia and nighttime voiding in drug-naïve patients with overactive bladder syndrome (OAB). PTNM involves delivering electrical pulses to stimulate the tibial nerve. The multicenter study included 120 subjects who underwent 12 weekly PTNM sessions using the NURO system. <br />The results showed a significant reduction in nocturia episodes per day after sessions 4, 8, and 12. Among subjects who reported at least 3 nocturia episodes per day at baseline, there was a reduction of 1.0 episodes after session 12 from baseline. Nighttime voiding frequency also decreased significantly after sessions 4, 8, and 12. Among subjects with at least 3 daily nighttime voids at baseline, there was a reduction of 0.8 voids after session 12. Furthermore, all subjects who reported nocturia in the baseline diary showed improvement after sessions 4, 8, and 12, with a reduction of 0.4 episodes after session 12.<br />In terms of safety, there were no serious adverse device effects or unanticipated adverse device effects. The most common adverse events reported were medical device site pain and pain in extremity, both at 3.3%.<br />Overall, the study suggests that PTNM using the NURO system can effectively reduce nocturia and nighttime voiding in drug-naïve patients with OAB. These findings are important in improving the quality of life for individuals suffering from OAB symptoms.

Keywords

percutaneous tibial neuromodulation

PTNM

nocturia

nighttime voiding

overactive bladder syndrome

tibial nerve stimulation

NURO system

multicenter study

adverse events

quality of life